ChemoCentryx, Inc., (CCXI), today announced that the Company's first quarter 2020 financial results will be released after market close on Monday, May 11, 2020. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on May 11, 2020 to discuss these results and to answer questions. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com.
NEW YORK, NY / ACCESSWIRE / March 10, 2020 / ChemoCentryx, Inc. (NASDAQ:CCXI) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 10, 2020 at 5:00 PM ...
Q4 2019 ChemoCentryx Inc Earnings Call
Joining me on the call today is Dr. Thomas Schall, President and Chief Executive Officer of ChemoCentryx, who will review the company's recent business and clinical progress. Following his comments, Susan Kanaya, Executive Vice President, Chief Financial and Administrative Officer of ChemoCentryx, will provide an overview of the company's financial highlights for the first quarter 2020 before turning the call back over to Tom for closing remarks.
Q1 2020 ChemoCentryx Inc Earnings Call
Enphase Energy makes the list Continue reading...
Today we will run through one way of estimating the intrinsic value of ChemoCentryx, Inc. (NASDAQ:CCXI) by estimating...
There's been a notable change in appetite for ChemoCentryx, Inc. (NASDAQ:CCXI) shares in the week since its full-year...
Market forces rained on the parade of ChemoCentryx, Inc. (NASDAQ:CCXI) shareholders today, when the analysts...
ChemoCentryx, Inc., (CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from a forty-six (46) patient Phase II dose-ranging trial in the orphan kidney disorder, primary Focal Segmental Glomerulosclerosis (FSGS). The LUMINA-1 trial tested CCX140, an orally-administered selective inhibitor of the chemokine receptor known as CCR2, in primary FSGS subjects. In the study, CCX140 did not demonstrate a meaningful reduction in proteinuria relative to the control group after 12 weeks of blinded treatment.
-- Announced positive topline data from pivotal Phase III ADVOCATE trial for ANCA-vasculitis in Q4; U.S. NDA filing expected mid-2020 -- -- “2020 4-Sight” on the horizon with.
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChemoCentryx (CCXI) delivered earnings and revenue surprises of 3.70% and 6.70%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
MOUNTAIN VIEW, Calif., March 03, 2020 -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2019 financial results will be.
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -16.67% and -32.49%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ChemoCentryx (CCXI) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out.
ChemoCentryx, Inc., (CCXI), today announced financial results for the first quarter ended March 31, 2020 and provided an overview of the Company's recent corporate highlights. "In the face of this global infection pandemic, we pause in sympathy for those suffering while we are reminded of the deep importance of our mission,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.
It's shaping up to be a tough period for ChemoCentryx, Inc. (NASDAQ:CCXI), which a week ago released some...
ChemoCentryx (CCXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well